skip to content

Sullivan, Sean D. 1960-

Overview
Works: 10 works in 18 publications in 2 languages and 376 library holdings
Roles: Thesis advisor, Editor
Classifications: RC591, 362.196238
Publication Timeline
Key
Publications about Sean D Sullivan
Publications by Sean D Sullivan
Most widely held works by Sean D Sullivan
Asthma's impact on society : the social and economic burden by Kevin B Weiss( Book )
9 editions published between 1999 and 2000 in English and held by 361 libraries worldwide
"One of the first comprehensive studies of the social and economic consequences of this chronic pulmonary illness, Asthma's Impact on Society assesses how communities, families, and individuals confront asthma and try to minimize its deleterious effects."--Jacket
Measurement and evaluation of outcomes in COPD ( Book )
1 edition published in 2003 in English and held by 6 libraries worldwide
Trends in cost, health status and functional outcomes among adult and pediatric patients with asthma 2000-2009 by Junho Jang( file )
1 edition published in 2012 in English and held by 1 library worldwide
Background: Asthma, a chronic inflammatory disease of the respiratory tract, has a high prevalence and substantial deleterious effects on health care costs in the U.S. Very few studies have examined recent trends in medical expenditures, health status, and functional outcomes among patients with asthma. Objectives: To examine the level and changes in medical costs, health status and functional outcomes in adults and pediatrics with asthma and to provide nationally representative estimates of medical costs from 2000 through 2009. Methods: Data from the 2000-2009 Medical Expenditure Panel Survey (MEPS) were used. Patients with asthma were identified by self-reported lifetime asthma diagnosis or medical condition based on International Classification of Disease, Ninth Revision, Clinical Modification. We studied the trends among three age groups: adults age 18 and above, adolescents ages 6-17, and children ages 0-5. Generalized linear models were used to examine the change in health care costs (adjusted for medical price inflation) and functional outcomes (number of work days lost (WDL) in adults and number of school days lost (SDL) in adolescents), while ordinary least square regression (OLS) was used for health status outcome (Physical Component Summary (PCS) and Mental Component Summary (MCS) from SF-12v2 Health Survey), adjusting for clinical and demographic characteristics, socioeconomic status and comorbidity. Two part models were used to estimate the medical costs of asthma. Results: Among adults, the mean PCS decreased 0.09 units annually (p<.01) and the trends of mean MCS was not significant. There was no significant change in the number of WDLs and marginal decrease in SDLs with 1.8% annually (p=.06). The trends of medical costs in adults and children with asthma were not significant. However the medical expenditures increased 2.5% annually during the ten year period in adolescents (p=.049). For the most recent year available (2009), the total incremental health care costs of asthma in the United States were $53 billion, $7 billion and $3 billion in adults, adolescents and children, respectively. Conclusion: This study finds that over a 10-year period, medical costs in asthma patients have increased or remained similar in all age groups, while outcomes have not improved. These data reflect a period of time in the US where increasing attention has been paid to asthma disease management. The lack of improvement in outcomes suggests that approaches to asthma management in the U.S. should be reexamined and modified
The impact of adherence and an intervention program on patient outcomes and costs in chronic hepatitis C infection by Cara Lyn McDermott( file )
1 edition published in 2012 in English and held by 1 library worldwide
Background and aims: Both observational studies and randomized trials have shown that higher medication adherence is associated with improved outcomes in patients with chronic hepatitis C infection (CHC). Little evidence exists on the association between adherence and health care costs. We sought to evaluate the impact of adherence on long-term outcomes and costs in a population of patients with CHC genotype 1 receiving peginterferon and ribavirin (PEG-RBV). We also evaluated the impact of a potential intervention to improve adherence on long-term costs and patient outcomes. Methods: We utilized a cohort Markov model describing the natural history of hepatitis C infection in a population of 50 year-old treatment-experienced adults to evaluate the following health states: CHC, compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, liver transplant, liver transplant survivor, and death. Using previously published data from the HALT-C trial, we modeled four levels of medication receipt: >80% PEG-RBV, >80% PEG/<80% RBV, <80% PEG/<80% RBV, and <80% PEG-RBV. The costs and quality-adjusted life years (QALYs) associated with moving patients to higher level of adherence was compared to the cost associated with a nursing-based intervention program. Time horizons of 5, 10, 20, 30 years and lifetime were evaluated. Results: Over a lifetime horizon, we compared patients with the highest adherence versus lowest adherence, and found the following reductions in liver-related events: 9.9% compensated cirrhosis, 4.7% decompensated cirrhosis, 1.4% hepatocellular carcinoma, and 0.5% liver transplant. The potential cost savings over a lifetime as patients move from a cohort of lower SVR to greater SVR ranged from $12,820-$62,690, with a 1% increase in SVR associated with savings of $2137-$3284. Conclusion: Interventions that increase patient adherence should improve outcomes in this population and have the potential to reduce costs
Bariatric surgery for severe obesity : determinants of use and economic impact by Rafael Alfonso-Cristancho( file )
1 edition published in 2013 in English and held by 1 library worldwide
Obesity in the U.S. population is a major public health problem with important clinical and economic implications. Bariatric surgery is currently the most effective long-term weight loss treatment for morbid obesity but less than 2% of the potentially eligible population has undergone the procedure. Our aims were to: 1) determine the patient characteristics associated with receiving a bariatric procedure among eligible patients; 2) identify patient characteristics that could be used as predictors of resource use and costs in severely obese patients with and without bariatric surgery; and 3) estimate and project the differences in long-term costs and outcomes across different clinically defined populations undergoing bariatric surgery compared to non-surgical approaches, refining a previously developed cost-effectiveness model. Methods: We used electronic medical records from members of Group Health Cooperative, based in Washington State to identify severely obese individuals, eligible for bariatric surgery, from 2004 to 2010. The probability of undergoing bariatric surgery was assessed using multivariate logistic regression adjusting for demographic and clinical characteristics, as well as patterns of practice. To determine the predictors of costs, we used generalized linear models for both groups with similar adjustment variables. We created a propensity score matched cohort based on specific characteristics previously identified at the date of surgery and the assigned index date for those who did not have surgery. Finally, we used these data to update a previously developed cost-effectiveness model to re-estimate the cost-effectiveness of bariatric surgery compared to non-surgical interventions. A total of 48,166 subjects were identified as eligible for bariatric surgery. Only 1,129 had bariatric surgery. The characteristics associated with having a bariatric procedure were: having insurance coverage for the procedure (OR=5.61; 4.71-6.68), higher body mass index (BMI) (1.10; 1.09-1.11), and older age (1.00; 1.00-1.01). The presence of comorbidities was associated with higher odds of having surgery. Examining comorbidities individually, only coronary heart disease was not associated with the surgery (0.96; 0.74-1.26). These characteristics changed over time, showing time trends towards increasing numbers of older adults and subjects with lower BMI having the procedure in the recent years. For costs, total annual costs were higher prior to surgery in the bariatric surgery group but decreased more (in absolute and relative terms) after the surgery compared to the non-surgical group. The total health care costs post-surgery for both groups were primarily driven by inpatient costs. The presence of comorbid conditions was associated with greater annual total costs in both groups. Major cardiovascular risk factors, such as coronary heart disease, hypertension, diabetes, and a higher comorbidity index, were associated with the highest increase in mean annual total costs. Despite being more expensive, bariatric surgery is cost-effective due to the impact on weight loss, which is associated with improved life expectancy and quality of life after the procedure. The incremental cost-effectiveness ratio of the bariatric surgery is sensitive to the presence of multiple comorbidities, mainly due to the reduction in the differences in the lifetime costs between surgical and non-surgical interventions for patients with multiple comorbidities. There are demographic, clinical, and insurance differences among subjects eligible for bariatric surgery that receive and do not receive the surgery. The presence of specific comorbid conditions increases the probability of surgery and is associated with higher total costs in this population. The cost-effectiveness of these procedures also depends on the presence of specific comorbid conditions. Understanding these differences could better inform the decisions that patients, clinicians, payers and policy-makers face in addressing the problem of increasing population obesity
Migraine-specific health resource utilization in chronic and episodic migraine across six countries by Joanna C Sanderson( file )
1 edition published in 2012 in English and held by 1 library worldwide
Background: Though studies have consistently revealed variation in resource utilization between chronic and episodic migraineurs, less is known about how these differences compare across countries. This research describes migraine-specific health resource utilization in chronic and episodic migraineurs across the United States (US), Canada, the United Kingdom (UK), Germany, France and Australia. Methods: A web-based screening survey, used to determine eligibility, was administered to 32,782 panelists who had previously reported experiencing headaches or migraines. Screener respondents (n=16,663) were eligible for the main questionnaire if they were ≥ 18 years of age, reported at least one headache (not associated with a cold, flu, head injury, or hangover) during the prior three months, and reported symptoms meeting the revised second International Classification of Headache Disorders (ICHD-IIR) diagnostic criteria for migraine. For the main questionnaire, respondents provided data concerning sociodemographic and clinical characteristics, attitudes, and utilization of health resources. Results: In bivariate analyses, the intensity of resource use differed across countries in each migraine type. In multivariate regression, the odds of visiting a provider for headache in the three months prior to completing the survey were higher in all countries relative to the US. The odds of having a typical provider of headache care were also higher in all countries relative to the US, but this was only significant for France (OR 1.85, 95% CI 1.04, 3.32). Relative to the US, the odds of having ever visited the emergency room for headache were significantly lower in France (OR 0.37, 95% CI 0.22, 0.62), the UK (OR 0.25, 95% CI 0.14, 0.45) and Germany (OR 0.31, 95% CI 0.18, 0.53). Respondents from Australia (OR 1.83, 95% CI 1.13, 2.96) and France (OR 1.51, 95% CI 1.00, 2.28) were more likely than those from the US to report ever trying more than three abortive agents. The odds of currently using a prescription abortive agent were significantly higher in France (OR 1.80, 95% CI 1.19, 2.74), the UK (OR 2.68, 95% CI 1.72, 4.17), Australia (OR 1.88, 95% CI 1.16, 3.03) and Germany (OR 2.10, 95% CI 1.37, 3.23) than in the US. Conclusion: Migraineurs differed significantly across countries in their demographic and clinical characteristics, and in the resources they utilized. Migraineurs from the US were generally less likely to report use of preventative services, such as recent provider visits and use of prescription abortive agents, and more likely to report emergency room visits, relative to migraineurs from the other countries studied. However, US migraineurs were also less likely to report ever being hospitalized for headache compared to migraineurs from Canada and Australia. Further research on the sources of this variability, including the influence of healthcare system design features, and the effects of the variability on outcomes in migraineurs is warranted
The economic burden of diabetic macular edemia in a working age and commercially insured population by Christopher John Wallick( file )
1 edition published in 2013 in English and held by 1 library worldwide
Diabetic Macular Edema (DME) is the leading cause of blindness amongst working age adults in most developed countries. Diagnosis and treatment of DME involves many visits to specialists, numerous medications, and great cost. The primary objective of this study was to describe the economic burden of DME in a commercially insured working age population. We conducted a retrospective cohort study using enrollment and health care claims information from a large database of commercially insured, working age adults. We matched a cohort of patients with a claim for DME 1:5 to a diabetic control group without DME and reported health care utilization and cost over a 1, 2 and 3 year period. The DME cohort had significantly more comorbidities and a higher Charlson Comorbidity Index (CCI) scores than the matched diabetic control cohort. Health care resource utilization rates were significantly higher in DME patients than diabetic control patients for every category. DME patients had claims for significantly higher counts of emergency, outpatient, and inpatient visits than the diabetic control cohort. The total number of days with a visit to any healthcare provider was on average more than 10 days greater in DME cohort patients than in non-DME diabetic patients (27.01 vs. 16.13 days). Among the DME cohort this represents, on average, a visit to a healthcare provider more than once every 2 weeks over the course of a year. We characterized utilization patterns for DME patients and compared them to matched non-DME diabetic patients. We found that DME patients utilized significantly more health care resources and accrued higher costs than the non-DME diabetic patients. DME patients also made more visits to health care professionals. The burden of disease for DME patients is large and may represent a challenge for patients that are trying to attend to family or work. The large and rising cost of treatment only adds burden to patients that are likely already missing work time to visit specialists. DME patients that have nearly 30 days per year with at least one provider visit are likely to have difficult decisions between seeking treatment and taking care of their family or going to work
Investigating the association between sedative hypnotic prescription exposures and motor vehicle crashes by Ryan Nicholas Hansen( file )
1 edition published in 2012 in English and held by 1 library worldwide
Background Motor vehicle crashes occur daily and may be fatal for the driver, passengers or bystanders. Crashes have been shown to be associated with certain medical conditions and exposure to prescription medications that impair the ability to drive. We sought to create a linked, population-based longitudinal crash and medical care use dataset and to evaluate the relationships between prescription opioid and sedative hypnotic medication exposures and automobile crashes in Washington State. Methods Crash data from the Washington State Department of Transportation from 2002 to 2009 were linked to medical, pharmacy and administrative data from the Group Health Cooperative (GHC) for all eligible members. Continuous prescription exposures were defined based on fill records for opioids and sedatives. We estimated multivariate extended Cox regressions to investigate the association between police-reported crashes and prescription fills for opioids and sedative hypnotics. We also stratified our analyses by the length of continuous prescription fills. Results A total of 676,694 subjects were included in the study. These individuals experienced 2.41 motor vehicle crashes per 100 person-years. Opioid prescription fills were associated with a hazard ratio of 1.37 (95% CI: 1.33 to 1.41). Stratifying opioid exposure by the length of continuous prescriptions resulted in a range of hazard ratios from 1.76 at 30 days (95% CI: 1.59 to 1.96) up to 11.33 at 120 days (95% CI: 9.18 to 13.98). Overall incident sedative prescriptions were associated with a hazard ratio of 2.23 (95% CI: 1.92 to 2.59). Stratifying continuous prescriptions by length revealed the highest risk group to be 121-240 days for all sedatives, trazodone and temazepam (overall HR: 6.84, 95% CI: 4.15 to 11.2). Zolpidem had no risk of crash in the first 30 days, yet risk climbed to a peak risk between 241-360 days (HR: 10.7, 95% CI: 3.9 to 29). Discussion The risk of motor vehicle crash is increased in people who fill prescriptions for opioids and sedative hypnotics. The hazard ratios estimated are equivalent to blood alcohol concentrations in excess of double the legal limit to drive. Public health may be improved by reducing driving time when using these medications
Implications and investigations of pharmacy benefit in the United States by Jonathan H Watanabe( file )
1 edition published in 2012 in English and held by 1 library worldwide
Medicaid clients are among the most at-risk members for poor health outcomes in society and this safety net health care is critical for assuring continuous access to medical care. We will describe the importance of curtailing unnecessary drug spend as well as generic utilization mechanisms already applied by payers. We will describe the background, implementation, and early findings of a prescriber feedback report card program to improve generic utilization in the Washington State Medicaid system. We quantified the association between possession of prescription drug coverage and likelihood of experiencing an emergency room [ER] visit and hospitalization in the adult United States population with private health insurance. For the outcomes of ER visits and hospitalizations, the ORs were 1.05 (95% confidence interval [CI], 0.95 to 1.15) and 1.07 (95% CI, 0.95-1.22) respectively using propensity score matching. Indicating a non-significant increase in odds of the outcomes of ER visit and hospitalization for patients possessing drug coverage . Multiple logistic regression produced similar findings. For the outcomes of ER visit and hospitalization, the adjusted ORs were 1.03 (0.96-1.12) and 1.01 (0.91-1.21) respectively. Prescription drug coverage in the United States was not associated with a reduction in likelihood of ER visit or hospitalization in this assessment pooling ten years of cross-sectional data. To estimate the reduction in adherence and medication supplied for patients that experience increases in average monthly copay over time for three therapeutically distinct drugs for chronic syndrome management using a nationally representative Commercial Claims databaseIncrease in $5 or more or $10 or more for average monthly copay was associated with a statistically significant reduction in MPR for all three drugs. Measured by generalized estimating equations, change in MPR varied from a minimum loss of 0.024 for simvastatin with a $5 or more increase in copay to a maximum loss of 0.063 for insulin glargine with $10 or more increase. This equates to a minimum loss of days supply 8.8 to 23.0 for simvastatin and insulin glargine respectively. Copay increases are associated with significant reductions in adherence of chronic medications necessary for optimal disease control
 
Alternative Names
Sullivan Sean 1960-....
Languages
English (17)
Slovenian (1)
Covers
Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.